Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

This presentation is classic for invasive mold sinusitis (often mucormycosis), a rapidly progressive angioinvasive infection in neutropenic or diabetic patients. Early mortality is high without prompt action. First-line therapy is expedited IV liposomal amphotericin B; voriconazole lacks activity against many Mucorales. Aggressive surgical debridement is crucial to remove necrotic tissue and reduce fungal burden; coordinate urgently with ENT and ophthalmology. Reverse predisposing factors: optimize glucose, reduce/stop steroids if possible, and consider G-CSF for marrow recovery. Waiting for biopsy or culture (Option C) delays lifesaving care; obtain tissue but do not withhold therapy. Oral fluconazole (Option D) has no activity against molds and is inappropriate. APRNs should activate sepsis protocols, arrange ICU-level monitoring when indicated, educate families about the need for potentially disfiguring but lifesaving surgery, and document serial exams/photographs to track response, adjusting antifungal therapy based on susceptibility and tolerability.

Pelvic radiation and some chemotherapies cause mucosal atrophy, fibrosis, and pelvic floor hypertonicity, leading to pain, dryness, and sexual avoidance. A multidisciplinary, behaviorally informed plan is most effective. Begin with regular use of nonhormonal vaginal moisturizers (several times weekly) and lubricants during sexual activity. A structured vaginal dilator program reduces stenosis and maintains elasticity; pairing this with pelvic floor physical therapy addresses hypertonicity and pain guarding. Topical lidocaine applied before penetration can reduce introital pain. Sex therapy—individual or couples—improves communication, reduces anticipatory anxiety, and rebuilds intimacy. For persistent genitourinary syndrome, carefully consider low-dose vaginal estrogen after oncology consultation; systemic absorption is low, but individualized risk–benefit is essential in hormone-sensitive cancers. Systemic estrogen for everyone (Option A) is inappropriate. Simple reassurance (Option C) neglects modifiable contributors. Opioids (Option D) do not address underlying dysfunction and carry risk. The APRN should normalize discussion of sexual health, provide handouts/demonstrations for dilator use, screen for mood/body-image concerns, and schedule follow-up to adjust the plan.

Fertility preservation is a critical component of supportive, patient-centered oncology care, especially when gonadotoxic therapy is planned. The optimal strategy for women is referral to a reproductive endocrinologist for timely counseling and consideration of oocyte or embryo cryopreservation before chemotherapy. These methods have the strongest evidence for future live birth potential. GnRH agonists may reduce chemotherapy-induced ovarian insufficiency in some settings but are not a substitute for cryopreservation and should be considered adjunctive. Deferring conversation until after treatment (Option A) often results in irreversible loss of fertility options. Presenting adoption as the only option (Option D) fails to honor patient autonomy and current reproductive technologies. The APRN coordinates expedited referral pathways, discusses expected treatment timelines, contraception during therapy, teratogenicity, and the psychosocial dimensions of fertility decisions. Documentation of counseling, insurance navigation, and linkage to financial resources or fertility preservation programs are essential parts of comprehensive care.

Immune checkpoint inhibitor (ICI)–related pneumonitis is an oncologic emergency that ranges from mild to life-threatening. In a symptomatic patient with hypoxemia and characteristic CT changes, the standard approach is to HOLD immunotherapy and initiate high-dose corticosteroids (e.g., prednisone 1–2 mg/kg/day or IV methylprednisolone for more severe presentations) after obtaining appropriate infectious work-up (viral panel, sputum cultures ± BAL if needed). Empiric antibiotics can be considered while infection is excluded, but steroids should not be delayed in a clinically convincing case. Early pulmonology involvement supports grading, bronchoscopy decisions, and oxygen/ventilatory management. Infliximab (Option C) is typically used for steroid-refractory ICI colitis, not first-line for pneumonitis; second-line agents for steroid-refractory pneumonitis include mycophenolate mofetil, IVIG, or infliximab in select scenarios, guided by specialists. Continuing ICI with minimal therapy (Option A) risks progression to respiratory failure. Outpatient deferment (Option D) is inappropriate given hypoxemia. APRN responsibilities include rapid recognition, initiation of steroids and monitoring, patient education on warning signs, and careful documentation to guide decisions about future rechallenge (generally avoided for grade ≥3).

Anthracyclines are DNA-binding vesicants; extravasation can cause progressive tissue necrosis. The correct response is to stop the infusion, leave the catheter in place to aspirate residual drug, apply cold compresses (to limit dispersion), photograph/measure the area, and rapidly initiate dexrazoxane—an approved antidote that chelates intracellular iron, reducing free-radical damage—ideally within 6 hours (given IV on days 1–3). Warm compresses and hyaluronidase (Option A) are appropriate for non–DNA-binding vesicants like vinca alkaloids, not anthracyclines. Removing the catheter and massaging (Option C) can spread the drug into tissues. Observation alone (Option D) risks deep injury. APRNs should ensure extravasation kits and dexrazoxane access, educate staff on drug-specific algorithms, consult plastics if extensive injury, and transition vesicant administration to central access when feasible. Documentation with photos and patient instructions for delayed ulceration are essential.